| Dr Emily M Purrenhage, PHARMD | |
|
1650 W Northern Lights Blvd, Anchorage, AK 99517-3340 | |
| (907) 339-0560 | |
| (907) 339-0519 |
| Full Name | Dr Emily M Purrenhage |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 1650 W Northern Lights Blvd, Anchorage, Alaska |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235439043 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 1965 (Alaska) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Emily M Purrenhage, PHARMD 1650 W Northern Lights Blvd, Anchorage, AK 99517-3340 Ph: (907) 339-0560 | Dr Emily M Purrenhage, PHARMD 1650 W Northern Lights Blvd, Anchorage, AK 99517-3340 Ph: (907) 339-0560 |
News Archive
U.S. Department of Health and Human Services Secretary Kathleen Sebelius today released an examination of the federal government's system to produce medications, vaccines, equipment and supplies needed for a health emergency, known as medical countermeasures. The Public Health Emergency Medical Countermeasure Enterprise Review: Transforming the Enterprise to Meet Long Range National Needs reviews the process and makes recommendations for a better approach.
Pluristem Therapeutics Inc. today announced that the independent DSMB approved the advancement to the intermediate dose level of the company's placenta derived cell therapy, PLX-PAD, in the Phase I clinical trial in Europe for the treatment of critical limb ischemia (CLI), the end stage of peripheral artery disease (PAD).
These changes, known as epigenetic modifications, control the activity of our genes without changing the actual DNA sequence. One of the main epigenetic modifications is DNA methylation, which plays a key role in embryonic development and the formation of different cell types, regulating when and where genes are switched on.
COVID-19 booster vaccines can now be given sooner than six months after their second dose to certain vulnerable people where this makes operational sense, as the UKHSA's Green Book has been updated.
› Verified 9 days ago
Ciara M Smith, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1650 W Northern Lights Blvd, Pharmacy Dept, Anchorage, AK 99517 Phone: 907-339-0560 | |
Kelly Cutrer, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 12045 Brandon St, Anchorage, AK 99515 Phone: 907-631-0300 Fax: 907-631-0632 | |
Dr. Kyle Patrick Smith, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 673 Mdg / Sghq, 5955 Zeamer Ave, Anchorage, AK 99506 Phone: 907-580-2778 | |
Dr. Remi Cristen Williamson, PHARMD, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4315 Diplomacy Dr, Anchorage, AK 99508 Phone: 907-729-2117 | |
Evan Michael Ambrose, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1650 W Northern Lights Blvd, Anchorage, AK 99517 Phone: 907-339-0560 | |
Timothy Paul Stone, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1200 N Muldoon Rd, Anchorage, AK 99504 Phone: 907-332-1004 | |
Jordan E Bell, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3260 Providence Dr Ste C520, Anchorage, AK 99508 Phone: 907-212-3420 Fax: 907-212-3429 |